Industries > Pharma > RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025

RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025

Prospects for siRNAs, shRNAs and ddRNAi Approaches

PUBLISHED: 24 June 2015
PAGES: 174
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
SKU: PHA0052 Categories: ,

RNAi therapies – new study showing you trends, R&D progress, and predicted revenues
When will RNAi therapies reach the market? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 180-page report provides 95 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this nascent pharmaceutical market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
• Joseph Payne, CEO, Arcturus Therapeutics
• J. Michael French, President and CEO, Marina Biotech
• Dr. Ana I. Jiménez, COO and R&D Director, Sylentis

See revenue forecasts for the most promising products in development
How will leading RNAi therapies perform to 2025 at world level? Our study forecasts sales of 11 products, including:
• ALN-TTR02 (patisiran)
• Vigil immunotherapy
• ALN-TTRsc (revusiran)
• ARC-520
• Atu027
• PF-655
• QPI-1002
• RXI-109
• siG12D-LODER
• SPC3649 (miravirsen)
• SYL040012

RNAi for Therapeutic Applications Technology and Market Forecast 2015-2025 Prospects for siRNAs, shRNAs and ddRNAi Approaches

Discover how high revenues can go. Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 4 regional markets plus the Rest of the World to 2025:
• US
• EU5
• Asia-Pacific
• Latin America
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that the US, in particular, will achieve high revenue growth to 2025. Developments worldwide in biotechnology infrastructure and RNAi therapy development will influence the market.

Leading companies and potential for market growth
Overall world revenue for RNAi therapies will reach $391m in 2018, our work forecasts. We predict strong revenue growth through to 2025. Market entry of novel therapies, investment from Big Pharma and high unmet medical needs in many markets will increase sales to 2025.

Our work shows you what organisations hold greatest potential. See Visiongain’s analysis of 11 leading companies, including these:
• Alnylam Pharmaceuticals
• Arrowhead Research
• Benitec Biopharma
• Gradalis Incorporated
• Quark Pharmaceuticals
• Roche Innovation Center Copenhagen (formerly Santaris Pharma)
• RXi Pharmaceuticals
• Silence Therapeutics
• Silenseed
• Sylentis
• Tekmira Pharmaceuticals.

A company profile gives you the following information where available:
• Historical revenues from 2010 to 2014
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

RNAi for Therapeutic Applications Technology and Market Forecast 2015-2025 Prospects for siRNAs, shRNAs and ddRNAi Approaches

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development – assess innovation, trends and possibilities
What about R&D – the pipeline for new drugs? You see trends for these areas and technologies:
• Small interfering RNA (siRNA) therapies
• Short hairpin RNA (shRNA) therapies
• DNA-directed RNAi (ddRNAi) therapies
• Delivery technologies such as lipid nanoparticles and viral vectors
• Other progress in RNAi therapy development.

RNAi therapy R&D is strong in siRNA-based therapies. Novel compounds and new delivery vectors with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.

What issues will affect the RNAi therapies industry?
Our new report discusses issues and events affecting the RNAi therapies market. You will find discussions, including qualitative analyses:
• Approval of other oligonucleotide products indicates a path to market acceptance
• Challenges exist with delivery of current RNAi therapies
• Big Pharma is investing in RNAi therapy developers
• Alternative approaches to gene silencing are advancing rapidly

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 report helps you
In summary, our 180-page report gives you the following knowledge:
• Revenue forecasts to 2025 for the world RNAi therapies market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2025 for the leading 5 regional markets – US, EU5, Asia-Pacific, Latin America and Rest of the World
• Predicted revenues of 11 leading drugs to 2025 – see potentials of top products
• Assessment of 11 leading companies – hear about products, results and strategies including pipeline analysis and recent developments
• Review of R&D pipelines – investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the RNAi therapies market and leading companies. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025

Download sample pages

Complete the form below to download your free sample pages for RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025

Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021


Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021


Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021


Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021